Five strategies for meeting the requirements of Project Optimus and improving the chances of approval

Published on: Nov 10, 2022

The study designs and dose-finding strategies that have dominated decades of oncology drug development are becoming obsolete as the FDA’s Project Optimus takes full effect. The agency is now heavily scrutinizing Phase 1 and 2 studies to see whether they identify the safest and most effective dose—while this change seems abrupt, it’s loomed over the field for a long time.

We’ve helped our clients adapt to the new standards with five best practices outlined in this article.


Get Exclusive PDF Access

Return to Insights Center

Related Insights

Webinar

Accelerating delivery of radiopharmaceutical trials

Oct 3, 2025

Webinar

Navigating the complexities of AML drug development

Oct 30, 2024

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Blog

PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers

Oct 4, 2024

Blog

Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications

Feb 4, 2025

Webinar

Advancing mRNA-based drug development and vaccine manufacturing

Jul 1, 2024

Webinar

Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)

Nov 12, 2024

Article

Q&A Project Optimus: What you need to know

Oct 11, 2022

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Blog

Celebrating 40 Years of Rare Disease Progress: WODC Highlights

Jun 6, 2023

Blog

Studying rare cancer patient populations using integrated genomic and real-world data

Aug 30, 2023

Whitepaper

How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU

Jun 28, 2023

Related Insights

Webinar

Accelerating delivery of radiopharmaceutical trials

Oct 3, 2025

Webinar

Navigating the complexities of AML drug development

Oct 30, 2024

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Blog

PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers

Oct 4, 2024

Blog

Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications

Feb 4, 2025

Webinar

Advancing mRNA-based drug development and vaccine manufacturing

Jul 1, 2024

Show more